Trial
NCT02759562
Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Cystic Fibrosis
Intervention
Andecaliximab
Why stopped
Discontinuation of development for this indication
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-17